Dual Diagnosis — When Addiction and Depression Overlap — How Baltimore Ketamine Clinic Approaches Treatment

two men sharing a supportive moment on a park bench by the baltimore waterfront during treatment for dual diagnosis addiction and depression in baltimore md

Co-occurring substance use disorder and major depressive disorder—often called dual diagnosis or co-occurring disorders—can be among the most complex presentations in behavioral health. In 2024, an estimated 21.2 million U.S. adults had both a mental illness and a substance use disorder, yet only 14.5% received treatment for both conditions.

Depression and substance use can reinforce one another, creating a cycle that is difficult to interrupt when care addresses only one side of the picture. At Baltimore Ketamine Clinic, we approach dual diagnosis with the understanding that depression symptoms, substance-use history, current recovery supports, and medical safety all matter in determining the next appropriate step.

Why Depression and Addiction Often Overlap

The relationship between depression and addiction is not always straightforward. For some people, depression or anxiety may precede substance use, particularly when alcohol, opioids, stimulants, or other substances are used in an attempt to cope with distress. For others, substance use, withdrawal, or the disruption it causes in daily life may contribute to persistent depressive symptoms. In many cases, both conditions develop alongside shared risk factors, including genetics, trauma exposure, chronic stress, and environmental circumstances.

This is why a careful evaluation matters. We look beyond a single symptom list to understand when mood symptoms began, how substance use has changed over time, what treatments have been tried, and whether symptoms continue outside periods of intoxication or withdrawal. That context helps determine whether someone may benefit from depression treatment, treatment for anxiety, medication review, psychotherapy, recovery support, or a combination of approaches.

Why Integrated Care Matters

When mental-health and substance-use concerns are treated in separate silos, important clinical details can be missed. A person may be told to stabilize substance use before discussing depression, while another provider may delay mental-health care until recovery feels more established. This can leave people without adequate support during a particularly vulnerable period.

Integrated care does not mean every person needs the same services or the same timeline. It means that treatment planning recognizes both conditions, considers how they interact, and coordinates care when appropriate. At our clinic, we do not view depression in isolation from a patient’s substance-use history, recovery goals, current medications, or outside care team.

For patients already working with a therapist, addiction specialist, primary-care clinician, or recovery program, coordination can be an important part of planning when the patient gives permission. Our approach is designed to support—not replace—appropriate addiction treatment, psychotherapy, and other medical care. To learn more about how we structure comprehensive support, visit our page on mental health treatment at our Baltimore, MD clinic.

Ketamine’s Potential Role in Dual Diagnosis Care

Research on ketamine in substance use disorders is still emerging. Small studies have examined ketamine alongside structured psychological treatment for alcohol use disorder, cocaine use disorder, and opioid use disorder. Some findings suggest potential benefits for abstinence or reduced substance use in selected settings, particularly when ketamine is paired with relapse-prevention therapy. However, the evidence remains limited, mixed in important areas such as craving, and insufficient to establish ketamine as a stand-alone addiction treatment.

That distinction matters. At Baltimore Ketamine Clinic, ketamine treatment for psychiatric indications is used off-label, and any consideration for a person with a substance use disorder history requires a thorough, individualized evaluation. A past substance use disorder does not automatically rule out a consultation, but it does make careful screening especially important.

We consider factors such as current substance use, recovery stability, medical and psychiatric history, prescribed medications, support systems, and whether coordination with an addiction-treatment provider would strengthen safety and continuity of care. You can also learn more about who may be a good candidate for ketamine therapy before scheduling an evaluation.

Ketamine Requires Careful Risk Assessment

Ketamine is a Schedule III controlled substance with recognized potential for misuse. That does not mean it is inappropriate for everyone with a substance use history, but it does mean candidacy should never be assumed.

A responsible evaluation considers the potential benefits alongside the risks of misuse, destabilization, medication interactions, active substance use, and the person’s broader recovery environment. Supervised treatment and ongoing clinical monitoring are important safeguards, but they do not replace individualized risk assessment.

Our goal is not to reflexively exclude people because they have lived with addiction. It is to make careful, clinically appropriate decisions that respect both the seriousness of treatment-resistant depression and the realities of recovery. Our post on ketamine’s potential to treat anxiety and addiction offers additional context on this evolving research.

Where SPRAVATO® May Fit

SPRAVATO® is a distinct, FDA-approved esketamine nasal spray treatment for adults with treatment-resistant depression. It is also approved, in conjunction with an oral antidepressant, for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior.

SPRAVATO® is not approved to treat substance use disorders. It is administered in a certified healthcare setting under supervision and requires at least two hours of monitoring after each treatment session. For someone with a co-occurring substance use disorder, candidacy requires an individualized discussion of diagnosis, recovery history, safety considerations, and the limits of the available evidence.

For patients whose primary concern is treatment-resistant depression, SPRAVATO® may be one option to discuss during a comprehensive evaluation. The right choice depends on the full clinical picture—not on a diagnosis alone.

Medication Management in the Context of Addiction

Medication decisions can require additional care when depression and substance use overlap. Some medications may carry dependence, withdrawal, interaction, or overdose risks, especially when alcohol, opioids, sedatives, or other substances are involved. Medication changes should be made only with a qualified prescriber who understands the person’s current treatment plan and substance-use history.

Our approach includes reviewing current prescriptions, previous medication trials, side effects, recovery goals, and the role of outside providers. We may also recommend coordination with a patient’s existing addiction-treatment team when appropriate and authorized by the patient. For more on this process, read our guide to medication management for mental health.

Addressing Stigma Without Minimizing Risk

Stigma remains a major barrier for people navigating both depression and addiction. Some patients arrive feeling as though their substance-use history makes them less deserving of careful psychiatric attention. We reject that framing.

Dual diagnosis is not a moral failure. It is a complex clinical situation that deserves compassion, honest discussion, and individualized care. At the same time, compassion does not mean minimizing risk. The most appropriate treatment plan is one that takes both depression and substance use seriously while helping the patient move toward greater stability and support.

FAQ

What is dual diagnosis, and how common is it?
Dual diagnosis, also called a co-occurring disorder, refers to the presence of both a mental-health condition and a substance use disorder. Depression and anxiety are common examples of mental-health conditions that may overlap with substance use. In 2024, approximately 21.2 million U.S. adults had both a mental illness and a substance use disorder.

Can patients with a history of addiction receive ketamine treatment?
A substance use disorder history does not automatically rule out an evaluation for ketamine treatment. However, it does require careful review of current substance use, recovery supports, medical history, prescribed medications, and potential risks. Each decision should be individualized.

Why is it important to address depression and addiction together?
Depression and substance use can influence one another in ways that complicate recovery. Addressing both helps clinicians better understand symptoms, treatment barriers, medication safety, relapse risks, and the supports a patient may need.

Does ketamine have its own addiction risk?
Ketamine is a Schedule III controlled substance with potential for misuse. This is one reason why careful screening, supervised administration, and ongoing clinical monitoring are especially important for patients with a substance use disorder history.

Does Baltimore Ketamine Clinic work with addiction-treatment providers?
When appropriate and with patient consent, we may coordinate with relevant members of a patient’s care team, including therapists, prescribers, primary-care clinicians, and addiction-treatment providers. Our goal is to support a care plan that accounts for the full clinical picture.

Key Takeaways

  • Dual diagnosis describes the overlap of a mental-health condition and a substance use disorder.
  • Depression and substance use can interact in different ways, so a careful evaluation should consider both conditions together.
  • Integrated treatment planning can reduce fragmentation and support safer, more coordinated care.
  • Research on ketamine for substance use disorders is emerging, but it is not an established stand-alone addiction treatment.
  • A history of substance use disorder does not automatically exclude someone from ketamine consideration, but it requires careful assessment.
  • SPRAVATO® is FDA-approved for specific depressive disorders, not for substance use disorders.
  • Stigma should never prevent someone from seeking compassionate, evidence-informed mental-health care.

Conclusion

Depression and addiction are not character flaws. They are health conditions that can overlap in complex ways and deserve careful, coordinated treatment.

At Baltimore Ketamine Clinic, we approach dual diagnosis by considering the whole person: depression symptoms, substance-use history, current recovery supports, medication safety, and treatment goals. If you or someone you love in Baltimore is navigating both depression and addiction and has not found adequate relief through conventional approaches, our ketamine-assisted addiction treatment and mental-health services can be a starting point for a thoughtful conversation about next steps. We invite you to schedule a consultation with our team today.

About Ivana Mitic

Ivana Mitic, CRNA, PMHNP, is the founder of Baltimore Ketamine Clinic. She brings training in anesthesiology and psychiatric mental-health care to the evaluation and treatment of patients with depression, anxiety, PTSD, OCD, and other treatment-resistant mental-health concerns. Her approach emphasizes individualized assessment, medication safety, and compassionate care.

Works Cited

Substance Abuse and Mental Health Services Administration. (2025, December 22). Co-occurring disorders and other health conditions. https://www.samhsa.gov/substance-use/treatment/co-occurring-disorders

Substance Abuse and Mental Health Services Administration. (2020). Substance use disorder treatment for people with co-occurring disorders: Treatment Improvement Protocol 42. https://library.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-02-01_004.pdf

National Institute on Drug Abuse. (2024, September 30). Co-occurring disorders and health conditions. https://nida.nih.gov/research-topics/co-occurring-disorders-health-conditions

Grabski, M., McAndrew, A., Lawn, W., et al. (2022). Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. American Journal of Psychiatry, 179(2), 152–162. https://pubmed.ncbi.nlm.nih.gov/35012326/

Tran, K., & MacDougall, D. (2024). Ketamine for adults with substance use disorders: Rapid review. Canadian Agency for Drugs and Technologies in Health. https://pubmed.ncbi.nlm.nih.gov/38588371/

U.S. Food and Drug Administration. (2025). SPRAVATO® (esketamine) nasal spray prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf

U.S. Drug Enforcement Administration. (2020). Drug fact sheet: Ketamine. https://www.dea.gov/sites/default/files/2020-06/Ketamine-2020.pdf

Medical Disclaimer

The information provided in this blog is for educational purposes only and does not constitute medical advice. Treatment outcomes vary by individual. Ketamine is used off-label for psychiatric indications. SPRAVATO® is FDA-approved for specific depressive disorders and is not approved to treat substance use disorders. Please consult with a qualified healthcare provider before beginning or changing any treatment plan.

Share Now :